Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
BMJ Publishing Group
2022-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/6/e004291corr1.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
by: Ming Zhang, et al.
Published: (2022-03-01) -
Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01) -
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01) -
Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial
by: Jincheng Guo, et al.
Published: (2025-04-01) -
Correction: Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
Published: (2022-02-01)